ReviewVaccines2023
Nanoparticle-Based Adjuvants and Delivery Systems for Modern Vaccines.
Review in Vaccines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A systematic review on vaccine developmental approaches: Evaluating efficacy, and addressing challenges of infectious diseases in the post-COVID-19 era.Virus research · 2026Pooled it
- Rationally designed tunable amphiphilic glycopolymers for safe and effective vaccine adjuvanticity.RSC advances · 2026Article
- Development and immunological evaluation of a multi-antigen recombinant adenovirus vaccine candidate against PRRSV and PCV2.BMC veterinary research · 2026Article
- Recent Advances in Vaccine Development Against Poultry Red Mite (Dermanyssus gallinae): A Literature Review on Native and Recombinant Antigens.Acta parasitologica · 2026Review
- Smart nanoparticle vaccines integrate nanotechnology artificial intelligence and immunoengineering for precision immunization.Discover nano · 2026Review
- Vaccine Therapy for the Management of Penile Cancer: Evidence, Opportunities and Challenges.Vaccines · 2026Review
- Assessment of the Immune Potential of Calcium Phosphate-Outer Membrane Protein-Nanoparticles (CaP-Omp-Nps) Adjuvanted Nano-Vaccine AgainstPharmaceutics · 2026Article
- The role of uropathogenicCurrent urology · 2026Review
- Synergistic Immunoenhancement of Recombinant PBP2a Vaccine Candidate by Biogenic Selenium Nanoparticles and MF59 Against Methicillin-Resistant Staphylococcus Aureus.Current microbiology · 2026Article
- Advances in Nanoparticles as Vaccine Adjuvants.Vaccines · 2026Article
- Nanotechnology-Enhanced Vaccines for Respiratory Infections: Opportunities and Challenges.International journal of nanomedicine · 2026Review
- Nano-adjuvants enhance the immunogenicity and safety of infectious bursal disease virus vaccines: a comprehensive review.Frontiers in immunology · 2026Review
- Programmed Aggregation of Lipidated Nitrobenzoselenadiazole as a Photo-Activatable Pyroptosis Inducer.Advanced healthcare materials · 2025Article
- The Elicitation of an Antigen-Specific Antibody Immune Response Using a Nanoparticulate Adjuvant Derived fromMolecules (Basel, Switzerland) · 2025Article
- A novel in vivo adjuvant activity of hydrocarbon isolated from Hippophae rhamnoides.Inflammopharmacology · 2025Article
- Beyond the Pandemic Era: Recent Advances and Efficacy of SARS-CoV-2 Vaccines Against Emerging Variants of Concern.Vaccines · 2025Review
- Q Fever Vaccines: Unveiling the Historical Journey and Contemporary Innovations in Vaccine Development.Vaccines · 2025Review
- Gold Nanoparticles as a Platform for Delivery of Immunogenic Peptides to THP-1 Derived Macrophages: Insights into Nanotoxicity.Vaccines · 2025Article
- Antibody Responses and the Vaccine Efficacy of Recombinant Glycosyltransferase and Nicastrin AgainstPathogens (Basel, Switzerland) · 2025Article
- Nanoimmunotherapy: the smart trooper for cancer therapy.Exploration of targeted anti-tumor therapy · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Ever since the development of the first vaccine, vaccination has had the great impact on global health, leading to the decrease in the burden of numerous infectious diseases. However, there is a constant need to improve existing vaccines and develop new vaccination strategies and vaccine platforms that induce a broader immune response compared to traditional vaccines. Modern vaccines tend to rely on certain nanotechnology platforms but are still expected to be readily available and easy for large-scale manufacturing and to induce a durable immune response. In this review, we present an overview of the most promising nanoadjuvants and nanoparticulate delivery systems and discuss their benefits from tehchnological and immunological standpoints as well as their objective drawbacks and possible side effects. The presented nano alums, silica and clay nanoparticles, nanoemulsions, adenoviral-vectored systems, adeno-associated viral vectors, vesicular stomatitis viral vectors, lentiviral vectors, virus-like particles (including bacteriophage-based ones) and virosomes indicate that vaccine developers can now choose different adjuvants and/or delivery systems as per the requirement, specific to combatting different infectious diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.